v2.4.0.6
Segment information Segment information (Tables)
12 Months Ended
Dec. 31, 2012
Segment Reporting [Abstract]  
Revenues
Revenues were as follows for the years ended December 31, 2012, 2011 and 2010 (in millions):
 
2012
 
2011
 
2010
Product sales:
 
 
 
 
 
Neulasta® 
$
4,092

 
$
3,952

 
$
3,558

NEUPOGEN® 
1,260

 
1,260

 
1,286

ENBREL
4,236

 
3,701

 
3,534

Aranesp® 
2,040

 
2,303

 
2,486

EPOGEN® 
1,941

 
2,040

 
2,524

Sensipar®/Mimpara®
950

 
808

 
714

Vectibix® 
359

 
322

 
288

Nplate® 
368

 
297

 
229

XGEVA® 
748

 
351

 
8

Prolia® 
472

 
203

 
33

Other
173

 
58

 

Total product sales
16,639

 
15,295

 
14,660

Other revenues
626

 
287

 
393

Total revenues
$
17,265

 
$
15,582

 
$
15,053

Geographical information with respect to revenues and long-lived assets
Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):
 
Years ended December 31,
 
2012
 
2011
 
2010
Revenues:
 
 
 
 
 
United States
$
13,415

 
$
11,985

 
$
11,636

ROW
3,850

 
3,597

 
3,417

Total revenues
$
17,265

 
$
15,582

 
$
15,053

 
December 31,
 
2012
 
2011
Long-lived assets:
 
 
 
United States
$
2,906

 
$
3,144

Puerto Rico
1,908

 
1,993

ROW
512

 
283

Total long-lived assets
$
5,326

 
$
5,420

Revenues earned from major customers
Certain information with respect to these customers for the years ended December 31, 2012, 2011 and 2010, was as follows (dollar amounts in millions):
 
2012
 
2011
 
2010
AmerisourceBergen Corporation:
 
 
 
 
 
Gross product sales
$
7,556

 
$
7,574

 
$
7,678

% of total gross revenues
34
%
 
36
%
 
38
%
% of U.S. gross product sales
43
%
 
45
%
 
47
%
McKesson Corporation:
 
 
 
 
 
Gross product sales
$
5,898

 
$
4,591

 
$
3,913

% of total gross revenues
27
%
 
22
%
 
19
%
% of U.S. gross product sales
32
%
 
27
%
 
24
%
Cardinal Health, Inc.:
 
 
 
 
 
Gross product sales
$
3,245

 
$
3,021

 
$
2,813

% of total gross revenues
15
%
 
14
%
 
14
%
% of U.S. gross product sales
19
%
 
18
%
 
17
%